Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
Quest will now offer dialysis-related clinical testing services to independent dialysis clinics
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Vasograin Plus represents a major advancement in the treatment of migraine
The submission is supported by results from the Phase 3b APEX study
Subscribe To Our Newsletter & Stay Updated